{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:50:34Z","timestamp":1794513034107,"version":"4.9.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40265-026-02342-w","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:30:26Z","timestamp":1780515026000},"page":"1365-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Misuse of Pregabalin and Gabapentin: A Second Systematic Review Update"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-7145","authenticated-orcid":false,"given":"Kirk E.","family":"Evoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daija","family":"Drain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pedigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-2042","authenticated-orcid":false,"given":"Jordan R.","family":"Covvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-1366","authenticated-orcid":false,"given":"Olivia","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2342_CR1","unstructured":"Cross AL, Viswanath O, Sherman AL. Pregabalin. Updated May 2, 2024. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK470341\/. Accessed 26 Jan 2026."},{"key":"2342_CR2","unstructured":"Yasaei R, Katta S, Patel P, Saadabadi A. Gabapentin. Updated Februrary 21, 2024. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493228\/. Accessed 26 Jan 2026."},{"issue":"4","key":"2342_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","volume":"77","author":"KE Evoy","year":"2017","unstructured":"Evoy KE, Morrison M, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403\u201326.","journal-title":"Drugs"},{"issue":"1","key":"2342_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","volume":"81","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125\u201356.","journal-title":"Drugs"},{"key":"2342_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.24953\/turkjped.2020.30","volume":"64","author":"BE Alan","year":"2022","unstructured":"Alan BE, Kizilkhan MP, Akgul S. Pregabalin abuse in adolescence: a case series. Turk J Pediatr. 2022;64:357\u201363.","journal-title":"Turk J Pediatr"},{"issue":"5","key":"2342_CR6","first-page":"700","volume":"16","author":"AA Alkhalaf","year":"2021","unstructured":"Alkhalaf AA, Bukhari RA, Alshehri EA, Alshehri SO, Badr AF. Abuse liability of gabapentin in the Saudi population after the pregabalin restriction: a cross-sectional study. J Taibah Univ Med Sci. 2021;16(5):700\u20135.","journal-title":"J Taibah Univ Med Sci"},{"key":"2342_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/ijpp\/riae071","volume":"33","author":"L Altayeb","year":"2025","unstructured":"Altayeb L, Zkriea A, El Imam E, GreebAlla K, Hassan R, Ahmed R, et al. Perceptions of community pharmacists regarding pregabalin abuse: a survey from Sudan. Int J Pharm Pract. 2025;33:52\u20137.","journal-title":"Int J Pharm Pract"},{"key":"2342_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/pds.5408","volume":"31","author":"TA Althunian","year":"2022","unstructured":"Althunian TA, Alomran MI, Alsagri GM, Alrasheed MM, Alshammari TM. The impact of regulatory restrictions on pregabalin use in Saudi Arabia: an interrupted time series analysis. Pharmacoepidemiol Drug Saf. 2022;31:577\u201382.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2342_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2024.111991","volume":"357","author":"AA Akca","year":"2024","unstructured":"Akca AA, Couchman L, Frinculescu A, Johnston A. Analysis of drug impregnated paper samples seized in English prisons between 2018 and 2020. Forensic Sci Int. 2024;357:111991.","journal-title":"Forensic Sci Int"},{"key":"2342_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2147\/IJGM.S405616","volume":"16","author":"M Antunovic","year":"2023","unstructured":"Antunovic M, Vucinic S, Kotur-Stevuljevic J, Krstic K, Jovic-Stosic J, Kilibarda V, et al. Rise of pregabalin poisoning and abuse cases in Serbia: a ten-year retrospective study. Int J Gen Med. 2023;16:1239\u201350.","journal-title":"Int J Gen Med"},{"key":"2342_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-258104","volume":"16","author":"H Awasthi","year":"2023","unstructured":"Awasthi H, Vohra A. Delirium following pregabalin discontinuation in an individual with no psychiatric or substance use history. BMJ Case Rep. 2023;16:e258104.","journal-title":"BMJ Case Rep"},{"key":"2342_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104287","volume":"123","author":"C Bharat","year":"2024","unstructured":"Bharat C, Gisev N, Barbieri S, Dobbins T, Larney S, Buizen L, et al. Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure: an analysis of overdose and all-cause mortality. Int J Drug Policy. 2024;123:104287.","journal-title":"Int J Drug Policy"},{"key":"2342_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/1556-4029.15500","volume":"69","author":"JJ Bierly","year":"2024","unstructured":"Bierly JJ, Chan-Hosokawa A. Gabapentin in drugged driving investigations. J Forensic Sci. 2024;69:986\u201392.","journal-title":"J Forensic Sci"},{"key":"2342_CR14","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/bcp.15976","volume":"90","author":"SM Bird","year":"2024","unstructured":"Bird SM. Opioid-related deaths and their counterpart by occurrence era, age group and complicated drugs: Scotland vs. England and Wales. Br J Clin Pharmacol. 2024;90:996\u20131015.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2342_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/02791072.2022.2050858","volume":"55","author":"U Bonnet","year":"2023","unstructured":"Bonnet U, Kanti A, Scherbaum N, Specka M. The role of gabapentinoids in the substance use pattern of adult Germans seeking inpatient detoxification treatment: a pilot study. J Psychoact Drugs. 2023;55(1):102\u201311.","journal-title":"J Psychoact Drugs"},{"key":"2342_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.592199","volume":"11","author":"U Bonnet","year":"2020","unstructured":"Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Grigoleit T, et al. Ranking the harm of psychoactive drugs including prescription analgesics to users and others: a perspective of German addiction medicine experts. Front Psychiatry. 2020;11:592199.","journal-title":"Front Psychiatry."},{"key":"2342_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2822","volume":"37","author":"U Bonnet","year":"2022","unstructured":"Bonnet U, McAnally HB. How prevalent and severe is addiciton on GABAmimetic drugs in an elderly German hospital population? Focus on gabapentinoids, benzodiazepines, and z-hypnotic drugs. Hum Psychopharmacol Clin Exp. 2022;37:e2822.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2342_CR18","doi-asserted-by":"publisher","first-page":"1041762","DOI":"10.3389\/fpsyt.2022.1041762","volume":"13","author":"U Bonnet","year":"2022","unstructured":"Bonnet U, Specka M, Kanti AK, Scherbaum N. Differences between users\u2019 and adiction medicine experts\u2019 harm and benefit assessments of licit and illicit psychoactive drugs: input for psychoeducation and legalization\/restriction debates. Front Psychiatry. 2022;13:1041762.","journal-title":"Front Psychiatry"},{"key":"2342_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.15288\/jsad.2020.81.681","volume":"81","author":"ME Buttram","year":"2020","unstructured":"Buttram ME, Kurtz SP. A qualitative examination of gabapentin misuse inside of treatment and recovery settings. Stud Alcohol Drugs. 2020;81:681\u20136.","journal-title":"Stud Alcohol Drugs"},{"key":"2342_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173482","volume":"221","author":"F Castillo","year":"2022","unstructured":"Castillo F, Jones JD, Luba RR, Mogali S, Foltin RW, Evans SM, et al. Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacol Biochem Behav. 2022;221:173482.","journal-title":"Pharmacol Biochem Behav"},{"issue":"5","key":"2342_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bja.2021.06.049","volume":"127","author":"T Chen","year":"2021","unstructured":"Chen T, Knaggs RD, Chen L. Association between opioid-related deaths and opioid dose and psychotropic medicines prescribed in general practice in England: a case-crossover study. Br J Anaesth. 2021;127(5):789\u201397.","journal-title":"Br J Anaesth"},{"issue":"9","key":"2342_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1177\/02698811221104065","volume":"36","author":"JM Corkery","year":"2022","unstructured":"Corkery JM, Guirguis A, Chiappini S, Martinotti G, Schifano F. Alprazolam-related deaths in Scotland, 2004\u20132020. J Psychopharmacol. 2022;36(9):1020\u201335.","journal-title":"J Psychopharmacol"},{"key":"2342_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.sapharm.2022.12.001","volume":"19","author":"JR Covvey","year":"2023","unstructured":"Covvey JR, Blakely ML, Singh R, Peckham AM, Evoy KE. Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Res Social Adm Pharm. 2023;19:599\u2013609.","journal-title":"Res Social Adm Pharm"},{"key":"2342_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.111140","volume":"331","author":"S Darke","year":"2022","unstructured":"Darke S, Peacock A, Duflou J, Farrell M, Lappin J. Characteristics of fatal \u2018novel\u2019 benzodiazepine toxicity in Australia. Forensic Sci Int. 2022;331:111140.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"2342_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1080\/15563650.2021.1965159","volume":"60","author":"S Darke","year":"2022","unstructured":"Darke S, Duflou J, Peacock A, Farrell M, Lappin J. Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020. Clin Toxicol. 2022;60(3):304\u201310.","journal-title":"Clin Toxicol"},{"issue":"4","key":"2342_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/10550887.2021.1907502","volume":"39","author":"H Deng","year":"2021","unstructured":"Deng H, Benhamou O, Lembke A. Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report. J Addict Dis. 2021;39(4):575\u20138.","journal-title":"J Addict Dis"},{"issue":"4","key":"2342_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.9740\/mhc.2021.07.225","volume":"11","author":"PH Desai","year":"2021","unstructured":"Desai PH, Taylor O, Shah KJ, Evoy KE, Peckham AM. Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Ment Health Clin. 2021;11(4):225\u201330.","journal-title":"Ment Health Clin"},{"key":"2342_CR28","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/dar.13918","volume":"43","author":"U Do","year":"2024","unstructured":"Do U, Perron P, Bruneau J, Larney S. Trends in toxicological findings in unintentional or stimulant toxicity deaths in Quebec, Canada, 2012-2021: has Quebec entered a new era of drug-related deaths? Drug Alcohol Rev. 2024;43:1613\u201324.","journal-title":"Drug Alcohol Rev"},{"key":"2342_CR29","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1111\/add.16306","volume":"118","author":"E Domzaridou","year":"2023","unstructured":"Domzaridou E, Carr MJ, Millar T, Webb RT, Ashcroft DM. Non-fatal overdose risk associated with prescriber opioid agonists concurrently with other medication: cohort study conducted using linked primary care, secondary care, and mortality records. Addiction. 2023;118:2374\u201383.","journal-title":"Addiction"},{"issue":"11","key":"2342_CR30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/15563650.2021.1892719","volume":"59","author":"L Dufayet","year":"2021","unstructured":"Dufayet L, Care W, Deheul S, Laborde-Casterot H, Nisse P, et al. Increase in pregabalin recreational use in adolescents in France. Clin Toxicol. 2021;59(11):1027\u201330.","journal-title":"Clin Toxicol"},{"key":"2342_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000001039","volume":"17","author":"HF Elarabi","year":"2023","unstructured":"Elarabi HF, Radwan DN, Adeen A, Marsden J, Lee AJ. Polysubstance use in adults with opioid use disorder receiving buprenorphine maintenance. J Addict Med. 2023;17:74\u20138.","journal-title":"J Addict Med"},{"key":"2342_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109400","volume":"234","author":"MS Ellis","year":"2022","unstructured":"Ellis MS, Buttram ME, Kasper ZA. Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder. Drug Alcohol Depend. 2022;234:109400.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"2342_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jamapsychiatry.2023.3145","volume":"80","author":"MS Ellis","year":"2023","unstructured":"Ellis MS, Xu KY, Tardelli VS, Fidalgo TM, Buttram ME, Grucza RA. Gabapentin use among individuals initiating buprenorphine treatment for opioid use disorder. JAMA Psychiat. 2023;80(12):1269\u201376.","journal-title":"JAMA Psychiat"},{"key":"2342_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109713","volume":"242","author":"MS Ellis","year":"2023","unstructured":"Ellis MS, Qureshi R, Buttram ME. Understanding motivations and use typologies of gabapentin with opioid agonist medications. Drug Alcohol Depend. 2023;242:109713.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2342_CR35","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11096-020-01217-8","volume":"43","author":"KE Evoy","year":"2021","unstructured":"Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse, and non-prescribed obtainment in a United States general population sample. Int J Clin Pharm. 2021;43(4):1055\u201364. https:\/\/doi.org\/10.1007\/s11096-020-01217-8.","journal-title":"Int J Clin Pharm"},{"key":"2342_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060104","volume":"12","author":"R Flemming","year":"2022","unstructured":"Flemming R. Patterns of pregabalin prescribing in four German federal states: analysis of routine data to investigate potential misuse of pregabalin. BMJ Open. 2022;12:e060104.","journal-title":"BMJ Open"},{"key":"2342_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.676224","volume":"12","author":"F Fonseca","year":"2021","unstructured":"Fonseca F, Lenahan W, Dart RC, Papaseit E, Dargan PI, Wood DM, et al. Non-medical use of prescription gabapentinoids (gabapentin and pregabalin) in five European countries. Front Psychiatry. 2021;12:676224.","journal-title":"Front Psychiatry"},{"key":"2342_CR38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40263-024-01095-y","volume":"38","author":"C Garnier","year":"2024","unstructured":"Garnier C, Schein M, Lacroix C, Jouve E, Soeiro T, Gentile G, et al. Patterns of pregabalin users from substance abuse treatment facilities: results from the French OPPIDUM Program from 2008\u20132022. CNS Drugs. 2024;38:743\u201351.","journal-title":"CNS Drugs"},{"issue":"4","key":"2342_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/20494637221095447","volume":"16","author":"R Ghose","year":"2022","unstructured":"Ghose R, Cowden F, Veluchamy A, Smith BH, Colvin LA. Characteristics of non-fatal overdoses and associated risk factors in patients attending a specialist community-based substance misuse service. Br J Pain. 2022;16(4):458\u201366.","journal-title":"Br J Pain"},{"key":"2342_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116028","volume":"339","author":"M Glancy","year":"2024","unstructured":"Glancy M, Palmateer N, Yeung A, Hickman M, Macleod J, Bishop J, et al. Risk of drug-related death associated with co-prescribing of gabapentinoids and Z-drugs among people receiving opioid-agonist treatment: a national retrospective cohort study. Psychiatry Res. 2024;339:116028.","journal-title":"Psychiatry Res"},{"issue":"1","key":"2342_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bja.2023.10.016","volume":"132","author":"A Hamina","year":"2024","unstructured":"Hamina A, Odsbu I, Hjellvik V, Lid TG, Clausen T, Skurtveit S. Fatal drug overdoses in individuals treated pharmacologically for chronic pain: a nationwide register-based study. Br J Anaesth. 2024;132(1):86\u201395.","journal-title":"Br J Anaesth"},{"key":"2342_CR42","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.4103\/0028-3886.333486","volume":"69","author":"KJ Harsha","year":"2021","unstructured":"Harsha KJ, Joshy EV, Aravinda RV, Poornima R. Chronic pregabalin abuse with subacute encephalopathy mimicking autoimmune encephalitis. Neurol India. 2021;69:1785\u20138.","journal-title":"Neurol India"},{"key":"2342_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/1742-6723.14297","volume":"35","author":"A Holford","year":"2023","unstructured":"Holford A, Martin C, Staib A, Harris K, Isoardi KZ. Introduction of Qscript real-time prescription monitoring system was associated with a fall in pregabalin poisoning presentations to a clinical toxicology unit. Emerg Med Australas. 2023;35:879\u201381.","journal-title":"Emerg Med Australas"},{"key":"2342_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jflm.2023.102635","volume":"101","author":"WR Huddleston","year":"2024","unstructured":"Huddleston WR, Lyness JR, Quinn A. Review of the demographic factors and toxicology related to deaths due to pregabalin in Northern Ireland. J Forensic Leg Med. 2024;101:102635.","journal-title":"J Forensic Leg Med"},{"issue":"2","key":"2342_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/00185787231206522","volume":"59","author":"SR Humpert","year":"2024","unstructured":"Humpert SR, Reveles KR, Bhakta K, Torrez SB, Evoy KE. Association of gabapentinoids with opioid-related overdose in the inpatient setting: a single center retrospective case-control study. Hosp Pharm. 2024;59(2):188\u201397.","journal-title":"Hosp Pharm"},{"key":"2342_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40261-021-01009-6","volume":"41","author":"EA Ibiloye","year":"2021","unstructured":"Ibiloye EA, Barner JC, Lawson KA, Rascati KL, Evoy KE, Peckham AM. Prevalence of and factors associated with gabapentinoid use and misuse among Texas Medicaid recipients. Clin Drug Investig. 2021;41:245\u201353.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"2342_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/npr2.12195","volume":"41","author":"H Ishikawa","year":"2021","unstructured":"Ishikawa H, Takeshima M, Ishikawa H, Ayabe N, Ohta H, Mishima K. Pregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: a case series and literature review. Neuropsychopharmacol Rep. 2021;41(3):434\u20139.","journal-title":"Neuropsychopharmacol Rep"},{"key":"2342_CR48","first-page":"2435","volume":"86","author":"KZ Isoardi","year":"2020","unstructured":"Isoardi KZ, Polkinghorne G, Harris K, Isbister GK. Pregabalin poisoning and rising recreational use: a retrospective observational series. Br J Pharmacol. 2020;86:2435\u201340.","journal-title":"Br J Pharmacol"},{"key":"2342_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2022.103322","volume":"80","author":"LJ Khave","year":"2023","unstructured":"Khave LJ, Noori M, Rahimi-Movaghar A, Noroozi A. Mangement of gabapentin misuse in a patient with previous history of opioid use disorder: case report. Asian J Psychiatr. 2023;80:103322.","journal-title":"Asian J Psychiatr"},{"key":"2342_CR50","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1111\/bcp.15352","volume":"88","author":"NJ Kalk","year":"2022","unstructured":"Kalk NJ, Chiu C, Sadoughi R, Baho H, Williams BD, Taylor D, et al. Fatalities associated with gabapentinoids in England (2004\u20132020). Br J Clin Pharmacol. 2022;88:3911\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"2342_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/pds.5628","volume":"32","author":"P Kamerman","year":"2023","unstructured":"Kamerman P. Rescheduling gabapentinoids had negligible effects on prescribing behavior by general practitioners in England. Pharmacoepidemiol Drug Saf. 2023;32:924\u201332.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"2342_CR52","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1093\/ajhp\/zxab486","volume":"79","author":"ZA Karavolis","year":"2022","unstructured":"Karavolis ZA, Su AB, Peckham AM. State-level response to gabapentin misuse in the United States: implications and future direction. Am J Health Syst Pharm. 2022;79(9):e143\u20138.","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"2342_CR53","first-page":"200","volume":"34","author":"S Ketenci","year":"2022","unstructured":"Ketenci S, Golboyu BE, Salbas E, Uzuner B, Ciftci B. The attitudes of Turkish physicians in the treatment of fibromyalgia; is \u201cPregabalinophobia\u201d the new reality of pain medicine? Agri. 2022;34(3):200\u20139.","journal-title":"Agri"},{"issue":"4","key":"2342_CR54","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpt.2314","volume":"110","author":"NF Khan","year":"2021","unstructured":"Khan NF, Bykov K, Glynn RJ, Barnett ML, Gagne JJ. Coprescription of opioids with other medications and risk of opioid overdose. Clin Pharmacol Ther. 2021;110(4):1011\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"2342_CR55","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18395","volume":"12","author":"OHT Kilic","year":"2024","unstructured":"Kilic OHT, Bayram ZN, Kiyat P, Karti O, Aral A, Munis ND, et al. Examination of optical coherence tomography findings in patients with pregabalin use disorder. PeerJ. 2024;12:e18395.","journal-title":"PeerJ"},{"key":"2342_CR56","first-page":"5378","volume":"27","author":"Z Kilic","year":"2023","unstructured":"Kilic Z, Ozaslan A. Abuse and addiction in gabapentinoid drug users for neuropathic pain. Eur Rev Med Pharmacol Sci. 2023;27:5378\u201389.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"2342_CR57","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1080\/15563650.2022.2101469","volume":"60","author":"A King","year":"2022","unstructured":"King A, Hill SL, Pucci M, Bailey G, Keating L, Macfarlane R, et al. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England. Clin Toxicol. 2022;60(10):1094\u20138.","journal-title":"Clin Toxicol"},{"key":"2342_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/cbm.2254","volume":"32","author":"M Kontu","year":"2022","unstructured":"Kontu M, Kantojarvi L, Hakko H, Riala K, Riipinen P. Misuse of prescribed psychotropic medication and drug crime offending: a follow-up case-control study of former adolescent psychiatric inpatients. Crim Behav Ment Health. 2022;32:124\u201337.","journal-title":"Crim Behav Ment Health"},{"key":"2342_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110830","volume":"324","author":"P Kriikku","year":"2021","unstructured":"Kriikku P, Ojanpera I. Pregabalin and gabapentin in non-opioid poisoning deaths. Forensic Sci Int. 2021;324:110830.","journal-title":"Forensic Sci Int"},{"issue":"7","key":"2342_CR60","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/j.amjmed.2022.02.039","volume":"135","author":"Y Kuo","year":"2022","unstructured":"Kuo Y, Liaw V, Yu X, Raji MA. Opioid and benzodiazepine substitutes: impact on drug overdose mortality in Medicare population. Am J Med. 2022;135(7):e194-206.","journal-title":"Am J Med"},{"issue":"4","key":"2342_CR61","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/02791072.2021.2013579","volume":"54","author":"L Langlume","year":"2022","unstructured":"Langlume L, Eiden C, Roy S, Taruffi F, Gambier J, Donnadieu-Rigole H, et al. Management of pregabalin use disorder: a case series. J Psychoact Drugs. 2022;54(4):386\u201391.","journal-title":"J Psychoact Drugs"},{"key":"2342_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108345","volume":"218","author":"C Mariottini","year":"2021","unstructured":"Mariottini C, Kriikku P, Ojanpera I. Concomitant drugs with buprenorphine user deaths. Drug Alcohol Depend. 2021;218:108345.","journal-title":"Drug Alcohol Depend"},{"key":"2342_CR63","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00414-024-03273-5","volume":"138","author":"C Mariottini","year":"2024","unstructured":"Mariottini C, Hakkinen M, Kriikku P, Ojanpera I. Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland. Int J Legal Med. 2024;138:2331\u20138.","journal-title":"Int J Legal Med"},{"issue":"19","key":"2342_CR64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.15585\/mmwr.mm7119a3","volume":"71","author":"CL Mattson","year":"2022","unstructured":"Mattson CL, Chowdhury F, Gilson TP. Trends in gabapentin detection and involvement in drug overdose deaths: 23 States and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep. 2022;71(19):664\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"2342_CR65","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/cpt.2717","volume":"112","author":"TA Miano","year":"2022","unstructured":"Miano TA, Wang L, Leonard CE, Brensinger CM, Acton EK, Dawwas GK, et al. Identifying clinical relevant drug-drug interactions with methadone and buprenorphine: a translational approach to signal detection. Clin Pharmacol Ther. 2022;112(5):1120\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"2342_CR66","doi-asserted-by":"publisher","first-page":"e1585","DOI":"10.1097\/PTS.0000000000000735","volume":"17","author":"FS Minhaj","year":"2021","unstructured":"Minhaj FS, Rappaport SH, Foster J, Gashlin LZ. Predictors of serious opioid-related adverse drug events in hospitalized patients. J Patient Saf. 2021;17(8):e1585\u20138.","journal-title":"J Patient Saf"},{"key":"2342_CR67","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/j.pain.0000000000003239","volume":"165","author":"S Muller","year":"2024","unstructured":"Muller S, Bailey J, Bajpai R, Helliwell T, Harrisson SA, Whittle R, et al. Risk of adverse outcomes during gabapentinoid therapy and factors associated with increased risk in UK primary care using the Clinical Practice Research Datalink: a cohort study. Pain. 2024;165:2282\u201390.","journal-title":"Pain"},{"key":"2342_CR68","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/jat\/bkaa132","volume":"45","author":"LK Nahar","year":"2021","unstructured":"Nahar LK, Murphy KG, Paterson S. Baclofen: to screen or not to screen in postmortem blood? J Anal Toxicol. 2021;45:612\u20138.","journal-title":"J Anal Toxicol"},{"key":"2342_CR69","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/jat\/bkab070","volume":"46","author":"LK Nahar","year":"2022","unstructured":"Nahar LK, Murphy K, Paterson S. Toxicological relevance of pregabalin in heroin users: a two-year postmortem population study. J Anal Toxicol. 2022;46:471\u20138.","journal-title":"J Anal Toxicol"},{"key":"2342_CR70","unstructured":"National Forensic Lab Information System. US Drug Enforcement Administration. NFLIS-Drug Special Report: gabapentin and pregabalin reported in NFLIS, 2011-2020. https:\/\/www.nflis.deadiversion.usdoj.gov\/publicationsRedesign.xhtml. Accessed 11 Nov 2025."},{"issue":"6","key":"2342_CR71","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/10398562221120365","volume":"30","author":"C Nayer","year":"2022","unstructured":"Nayer C, Sveticic J, Abeysundera H, Bui TA. Comparison of the characteristics of patients treated with sublingual vs. long-acting injectable buprenorphine formulations for treatment of opioid use disorder: a retrospective cohort study. Australas Psychiatry. 2022;30(6):754\u20138.","journal-title":"Australas Psychiatry"},{"key":"2342_CR72","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11419-023-00666-w","volume":"42","author":"MA Neukamm","year":"2024","unstructured":"Neukamm MA, Halter S, Auwarter V, Schmitt G, Giorgetti A, Bartel M. Death after smoking of fentanyl, 5F-ADB, 5F-MDMB-P7AICA and other synthetic cannabinoids with a bucket bong. Forensic Toxicol. 2024;42:82\u201392.","journal-title":"Forensic Toxicol"},{"key":"2342_CR73","doi-asserted-by":"publisher","first-page":"1309654","DOI":"10.3389\/fpubh.2023.1309654","volume":"11","author":"M Novotny","year":"2024","unstructured":"Novotny M, Bulla J, Hubl D, Fischer SKM, Grosshans M, Gutzeit A, et al. Pregabalin use in forensic hospitals and prisons in German speaking countries: a survey study of physicians. Front Public Health. 2024;11:1309654.","journal-title":"Front Public Health"},{"key":"2342_CR74","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1016\/j.japh.2020.12.012","volume":"61","author":"G Oh","year":"2021","unstructured":"Oh G, Slavova S, Freeman PR. Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance. J Am Pharm Assoc Wash. 2021;61:e86-92.","journal-title":"J Am Pharm Assoc Wash"},{"key":"2342_CR75","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jat\/bkaa118","volume":"45","author":"NC Okoye","year":"2021","unstructured":"Okoye NC, McMillin GA. Patterns of neonatal co-exposure to gabapentin and commonly abused drugs observed in umbilical cord tissue. J Anal Toxiol. 2021;45:506\u201312.","journal-title":"J Anal Toxiol"},{"issue":"4","key":"2342_CR76","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/02698811221080465","volume":"36","author":"M Osler","year":"2022","unstructured":"Osler M, Jorgensen MB. Association of benzodiazepines, Z-drugs, pregabalin, and melatonin with traffic accidents: a nationwide cohort and case-crossover study in Danish adults. J Psychopharmacol. 2022;36(4):470\u20138.","journal-title":"J Psychopharmacol"},{"key":"2342_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.115996","volume":"241","author":"DY Ovat","year":"2024","unstructured":"Ovat DY, Aslan R, Kirli U, Akgur SA. Methamphetamine as the most common concomitant substance used with pregabalin misuse. J Pharm Biomed Anal. 2024;241:115996.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"2342_CR78","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1097\/MJT.0000000000001544","volume":"30","author":"A Panwar","year":"2023","unstructured":"Panwar A, Vaidyanathan S, Udupa S, Munoli RN, Praharaj SK. Anticraving effect of N-acetyl cysteine in a patient with pregabalin and alcohol dependence. Am J Ther. 2023;30(6):e597\u20138.","journal-title":"Am J Ther"},{"key":"2342_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.640264","volume":"12","author":"G Papazisis","year":"2021","unstructured":"Papazisis G, Spachos D, Siafis S, Pandria N, Deligianni E, Tsakiridis I, et al. Assessment of the safety signal for the abuse potential of pregabalin and gabapentin using the FAERS database and big data search analytics. Front Psychiatry. 2021;12:640264.","journal-title":"Front Psychiatry."},{"key":"2342_CR80","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jpeds.2020.10.030","volume":"229","author":"SW Patrick","year":"2021","unstructured":"Patrick SW, Slaughter JC, Harrell FE Jr, Martin PR, Hartmann K, Dudley J, et al. Development and validation of a model to predict neonatal abstinence syndrome. J Pediatr. 2021;229:154\u201360.","journal-title":"J Pediatr"},{"issue":"3","key":"2342_CR81","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/02791072.2020.1861392","volume":"53","author":"E Peles","year":"2020","unstructured":"Peles E, Sason A, Schreiber S, Adelson M. Pregabalin misuse: motives, pattern, and knowledge about its risks among patients in methadone maintenance treatment. J Psychoact Drugs. 2020;53(3):238\u201346.","journal-title":"J Psychoact Drugs"},{"key":"2342_CR82","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.3390\/ijerph18157818","volume":"18","author":"M Perello","year":"2021","unstructured":"Perello M, Rio-Aige K, Guayta-Escolies R, Gascon P, Rius P, Jambrina AM, et al. Evaluation of medicine abuse trends in community pharmacies: the Medicine Abuse Observatory (MAO) in a region of southern Europe. Int J Environ Res Public Health. 2021;18:7818.","journal-title":"Int J Environ Res Public Health"},{"key":"2342_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195942","volume":"13","author":"M Perello","year":"2024","unstructured":"Perello M, Rio-Aige K, Rius P, Perez-Cano FJ, Rabanal M. Characteristics of non-therapeutic pregabalin users detected by a community pharmacies network in a region of Southern Europe. J Clin Med. 2024;13:5942.","journal-title":"J Clin Med"},{"issue":"5","key":"2342_CR84","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/10790268.2021.2024709","volume":"46","author":"CS Polat","year":"2023","unstructured":"Polat CS, Konak HE, Akinci MG, Onat SS, Altas EU. Misuse of gabapentinoids (pregabalin and gabapentin) in patients with neuropathic pain related to spinal cord injury. J Spinal Cord Med. 2023;46(5):859\u201364.","journal-title":"J Spinal Cord Med"},{"key":"2342_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109952","volume":"249","author":"D Powell","year":"2023","unstructured":"Powell D, Shetty KD, Peet ED. Trends in overdose deaths involving gabapentinoids and Z-drugs in the United States. Drug Alcohol Depend. 2023;249:109952.","journal-title":"Drug Alcohol Depend"},{"key":"2342_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104104","volume":"141","author":"D Powell","year":"2025","unstructured":"Powell D, Peet ED, Pacula RL. Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States. Int J Drug Policy. 2025;141:104104.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"2342_CR87","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/15563650.2024.2309321","volume":"62","author":"M Pucci","year":"2024","unstructured":"Pucci M, Jutley GS, Looms J, Ford L. N-desethyl isotonitazene detected in polydrug users admitted to hospital in Birmingham, United Kingdom. Clin Toxicol Phila. 2024;62(1):19\u201325.","journal-title":"Clin Toxicol Phila"},{"key":"2342_CR88","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.vaa.2021.06.007","volume":"48","author":"R Reader","year":"2021","unstructured":"Reader R, Olaitan O, McCobb E. Evaluation of prescribing practices for gabapentin as an analgesic among veterinary professionals. Vet Anaesth Analg. 2021;48:775\u201381.","journal-title":"Vet Anaesth Analg"},{"key":"2342_CR89","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/bcp.15073","volume":"88","author":"SJ Rietjens","year":"2022","unstructured":"Rietjens SJ, Sikma MA, Hunault CC, de Lange DW, Hondebrink L. Pregabalin poisoning: evaluation of dose-toxicity relationship. Br J Clin Pharmacol. 2022;88:1288\u201397.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2342_CR90","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/20961790.2021.1991075","volume":"6","author":"SB Riley","year":"2021","unstructured":"Riley SB, Garbutt K, Crow C, Isbell TS, Scalzo AJ. Gabapentin prevalence: clinical and forensic experience in St. Louis, Missouri, USA. Forensic Sci Res. 2021;6(3):218\u201323.","journal-title":"Forensic Sci Res"},{"key":"2342_CR91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/pmrj.13026","volume":"16","author":"AJ Rothka","year":"2024","unstructured":"Rothka AJ, Jonik S, Cherin N. Gabapentin withdrawal masquerading with stroke-like symptoms. PM R. 2024;16:303\u20134.","journal-title":"PM R"},{"key":"2342_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-16051-6","volume":"23","author":"L Servais","year":"2023","unstructured":"Servais L, Huberland V, Richelle L. Misuse of pregabalin: a qualitative study from a patient\u2019s perspective. BMC Public Health. 2023;23:1339.","journal-title":"BMC Public Health"},{"key":"2342_CR93","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/ijpp\/riae045","volume":"32","author":"JB Shammah","year":"2024","unstructured":"Shammah JB, Scott J, Wazaify M. Prescription and nonprescription drug misuse and abuse in community pharmacies in Iraq: a cross-sectional survey. Int J Pharm Pract. 2024;32:461\u20139.","journal-title":"Int J Pharm Pract"},{"key":"2342_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.legalmed.2024.102522","volume":"71","author":"K Shintani-Ishida","year":"2024","unstructured":"Shintani-Ishida K, Kawamoto M, Kondo H, Onoe T, Ikegaya H. Fatal pregabalin poisoning in Japan: a case report. Leg Med (Tokyo). 2024;71:102522.","journal-title":"Leg Med (Tokyo)"},{"issue":"4","key":"2342_CR95","first-page":"1238","volume":"33","author":"T Svalina","year":"2021","unstructured":"Svalina T, Palandacic AK. Pregabalin abuse: a case report. Psychiatr Danub. 2021;33(4):1238\u20139.","journal-title":"Psychiatr Danub"},{"key":"2342_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780","volume":"12","author":"M Tambon","year":"2021","unstructured":"Tambon M, Ponte C, Jouanjus E, Fouilhe N, Micallef J, Lapeyre-Mestre M, et al. Gabapentinoid abuse in France: evidence on health Ccnsequences and new points of vigilance. Front Psychiatry. 2021;12:639780.","journal-title":"Front Psychiatry"},{"key":"2342_CR97","volume":"10","author":"VS Tardelli","year":"2022","unstructured":"Tardelli VS, Bianco MCM, Prakash R, Segura LE, Castaldelli-Maia JM, Fidalgo TM, et al. Overdose deaths involving non-BZD hypnotic\/sedatives in the USA: trends analyses. Lancet Reg Health Am. 2022;10:100190.","journal-title":"Lancet Reg Health Am"},{"issue":"3","key":"2342_CR98","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/02791072.2023.2226138","volume":"56","author":"C Teker","year":"2024","unstructured":"Teker C, Aslan R, Ipekci C, Tokdemir M, Akgur SA. Pregabalin qualitative detection in Turkish forensic cases between 2017 to 2018. J Psychoact Drugs. 2024;56(3):380\u20136.","journal-title":"J Psychoact Drugs"},{"key":"2342_CR99","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s12024-023-00694-3","volume":"20","author":"I Thompson","year":"2024","unstructured":"Thompson I, Gadsby Z, Martin J, Thompson M, Tse R. Gabapentinoid detection in coronial casework in Gold Coast, Australia: a 5-year retrospective study. Forensic Sci Med Pathol. 2024;20:847\u201351.","journal-title":"Forensic Sci Med Pathol"},{"key":"2342_CR100","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jsps.2023.05.009","volume":"31","author":"A Yasmeen","year":"2023","unstructured":"Yasmeen A, Syed MH, Alqahtani SS, Syed NK, Meraya AM, Wazaify M, et al. Suspected inappropriate use of prescription and non-prescription drugs among requesting customers: a Saudi community pharmacists\u2019 perspective. Saudi Pharm J. 2023;31:1254\u201364.","journal-title":"Saudi Pharm J"},{"issue":"4","key":"2342_CR101","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/08897077.2021.1891602","volume":"42","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Castracane AR, Winstanley EL. Assessment of gabapentin misuse using prescription drug monitoring program data. Subst Abus. 2021;42(4):454\u20139.","journal-title":"Subst Abus"},{"key":"2342_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109429","volume":"235","author":"D Zhao","year":"2022","unstructured":"Zhao D, Nunes AP, Baek J, Lapane KL. An algorithm to identify gabapentin misuse and\/or abuse in administrative claims data. Drug Alcohol Depend. 2022;235:109429.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2342_CR103","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/add.15189","volume":"116","author":"L Zhou","year":"2021","unstructured":"Zhou L, Bhattacharjee S, Kwoh K, Tighe PJ, Reisfield GM, Malone DC, et al. Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. Addiction. 2021;116(4):819\u201330.","journal-title":"Addiction"},{"key":"2342_CR104","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1111\/add.16261","volume":"118","author":"T Soeiro","year":"2023","unstructured":"Soeiro T, Pradel V, Lapeyre-Mestre M, Micallef J. Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: a nation-wide, repeated cross-sectional study. Addiction. 2023;118:1984\u201393.","journal-title":"Addiction"},{"key":"2342_CR105","unstructured":"US Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed 26 Jan 2026."},{"key":"2342_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.639780","volume":"12","author":"M Tambon","year":"2021","unstructured":"Tambon M, Ponte C, Jouanjus E, Fouilhe N, Micallef J, Lapeyre-Mestre M, et al. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021;12:639780.","journal-title":"Front Psychiatry"},{"key":"2342_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101424","volume":"57","author":"T Soeiro","year":"2025","unstructured":"Soeiro T, Uras M, Jouanjus E, Lapeyre-Mestre M, Micallef J. High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study. Lancet Region Health. 2025;57:101424.","journal-title":"Lancet Region Health"},{"key":"2342_CR108","first-page":"1","volume":"12","author":"AM Peckham","year":"2018","unstructured":"Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? Subst Abuse. 2018;12:1\u20138.","journal-title":"Subst Abuse"},{"issue":"1","key":"2342_CR109","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/bcp.12277","volume":"78","author":"V Kapil","year":"2013","unstructured":"Kapil V, Green JL, Le Lait M, Wood DM, Dargan PI. Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2013;78(1):190\u20131.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2342_CR110","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11920-025-01631-7","volume":"27","author":"N Vadiei","year":"2025","unstructured":"Vadiei N, Evoy KE, Grundmann O. The impact of diverse kratom products on use patterns, dependence, and toxicity. Curr Psychiatry Rep. 2025;27(10):584\u201392.\u00a0https:\/\/doi.org\/10.1007\/s11920-025-01631-7.\u00a0","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"2342_CR111","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/10550887.2020.1788914","volume":"38","author":"JR Covvey","year":"2020","unstructured":"Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis. 2020;38(4):506\u201313. https:\/\/doi.org\/10.1080\/10550887.2020.1788914.","journal-title":"J Addict Dis"},{"issue":"4","key":"2342_CR112","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/00952990.2025.2502743","volume":"51","author":"KE Evoy","year":"2025","unstructured":"Evoy KE, Acharya SE, Bloomfield M, Torrez S, Covvey JR, Witry M. Hemp-derived tetrahydrocannabinol (THC) and kratom related health claims provided by smoke shop employees: a secret shopper study. Am J Drug Alcohol Abuse. 2025;51(4):502\u201310.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2342_CR113","first-page":"1","volume":"14","author":"KE Evoy","year":"2020","unstructured":"Evoy KE, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano S, et al. Receipt of substance use counseling among ambulatory patients prescribed opioids in the United States. Subst Abuse. 2020;14:1\u20134.","journal-title":"Subst Abuse"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02342-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:02:16Z","timestamp":1784203336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02342-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2342"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02342-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kirk E. Evoy, Daija Drain, Justin Pedigo, Jordan R. Covvey, and Olivia Ramey have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KE: conceptualization, methodology, data curation, writing (original draft), writing (editing and reviewing), supervision, project administration; DD: data curation, writing (original draft), writing (editing and reviewing); JP: data curation, writing (original draft), writing (editing and reviewing); JC: writing (editing and reviewing), visualization; OR: data curation, writing (original draft), writing (editing and reviewing). All authors have read and approved the final version.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}